Bilimsel Yayınlar
1. Demir, M., Akpolat, C., Karapapak, M., Sendul, S. Y., & Guven, D. (2022). A double-blinded randomized clinical trial for pain perception: The efficacy and safety of topical cold saline solution anesthesia in phacoemulsification. Indian Journal of Ophthalmology, 70(1), 124.
2. Demir, A. G., Olgun, A., Guven, D., Demir, M., Sendul, S. Y., Akarsu Acar, O. P., & Kacar, H. (2019). The effect of combined phacotrabeculectomy, trabeculectomy and phacoemulsification on the corneal endothelium in the early stage: a preliminary study. International Ophthalmology, 39(9), 2121-2128.
3. Demir, M. (2015). Effect of bevacizumab, which remain after withdrawal of the first dose/s from a single-use vial on diabetic macular edema. International Journal of Basic & Clinical Pharmacology (IJBCP), 4(1).
4. Demir, M., Oba, E., Guven, D., Acar, Z., & Cinar, S. (2014). Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion. International Journal of Clinical Pharmacy, 36(2), 438-442.
5. Demir, M., Dirim, B., Acar, Z., Sendul, Y., & Oba, E. (2014). Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. Indian Journal of Ophthalmology, 62(3), 279.
6. Demir, M., Oba, E., Sensoz, H., & Ozdal, E. (2014). Retinal nerve fiber layer and ganglion cell complex thickness in patients with type 2 diabetes mellitus. Indian Journal of Ophthalmology, 62(6), 719.
7. Demir, M., Can, E., Guven, D., Cinar, S., & Demir, A. (2013). Macular Laser Grid alone versus combined with Intravitreal Triamcinolone plus Bevacizumab for Diabetic Macular Edema. Journal of Pharmaceutical and Scientific Innovation (JPSI), 2(4): 36-39.
8. Demir, M., Ozel, A., Dirim, B., Ozdal, E., & Can, E. (2013). Effects of single dose intravitreal bevacizumab injection on visual acuity, central macular thickness and ocular blood flow in patients with diabetic macular edema. International Eye Science, 13(3).
